Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.74

-1.3%

Dec 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1812)	1/15/2008 12:53:00 PM
From: Jibacoa	Read Replies (1) of 3722

ACEL Was up 22.85%, but is up only 14% at present.<g> Volume of 330.Ks is about 4x its ADV. bigcharts.marketwatch.com It announced that Strativa, a subsidiary of PRX, has acquired the commercialization rights in the U.S. to ONCONASE from ACEL. ONCONASE is in PIII for the treatment mesothelioma & was previously granted orphan drug status & fast-track development status by the FDA. The short ratio is >18x the ADV.It seems that with some good news & a better general market mood ACEL could get to the $4 level for a 100% gain from present levels.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next